ENIn Germany, hyperthermia – heating a tumour – is used alongside radiotherapy or chemotherapy, not instead of them. A family searching for options may find clinics offering «cancer heat therapy» and wonder whether it is real treatment or a promise.
Heat treatment for cancer in Germany – hyperthermia – means warming a tumour or body region under medical control, recognised only as an addition to radiotherapy or chemotherapy, not as a replacement. See also cancer treatment in Germany. Below: how heat works, its types, the evidence, warning signs and how treatment is organised.
How hyperthermia works
Heat should make a tumour more sensitive to the main treatment rather than destroy it alone. Tissue is warmed to about 40–43 °C, just above a very high fever. Healthy tissue sheds heat through increased blood flow, while a tumour’s blood flow rises little, so it can get hotter.
Warmed cancer cells become more sensitive to radiation and some chemotherapy drugs, and mild heating briefly improves the tumour’s blood flow and oxygen supply, which can strengthen radiotherapy. Heat alone is not considered a cancer treatment: the US National Cancer Institute notes that hyperthermia is almost always used with other treatments.
Types of hyperthermia
The types differ in what is heated and how. Local hyperthermia treats tumours near the surface: an applicator outside the body heats a small area with microwaves, radio waves or ultrasound, together with radiotherapy or, less often, chemotherapy.
Regional deep hyperthermia treats tumours of the pelvis, abdomen or limbs. The patient lies inside a ring of antennas emitting electromagnetic waves that warm a whole region – with a leg sarcoma, the entire leg – while probes monitor the temperature. Sessions come shortly before or after radiotherapy, or during chemotherapy.
Whole-body hyperthermia heats the entire body in a thermal chamber or under hot water blankets. HIPEC is different: during surgery, after removing tumour deposits in the abdomen, the surgeon rinses the cavity with warmed chemotherapy. Each has its own indications.
Hyperthermia cancer treatment in Germany: where studies show a benefit
The benefit is best documented in high-risk soft tissue sarcoma – large, deep, high-grade tumours. In the randomised EORTC 62961 trial, led from LMU University Hospital in Munich, 341 patients had chemotherapy before surgery, alone or with regional hyperthermia. With heat, local progression was less frequent, and after a median 11.3 years of follow-up, ten-year survival was 52.6% versus 42.7%. The German sarcoma guideline allows but does not require the combination, given limited availability; see sarcoma treatment.
The standard of cervical cancer treatment at a locally advanced stage is radiotherapy with cisplatin; if cisplatin is contraindicated, radiotherapy with deep hyperthermia is an established alternative. A Cochrane review suggests better tumour control and survival on limited data, and Germany’s Cancer Information Service advises hyperthermia within a trial where possible. For breast cancer recurring on the chest wall, the radiation oncology society DEGRO says hyperthermia added to re-irradiation can further improve tumour control, though it is not standard.
German specialist societies recommend that heat treatment for prostate cancer in Germany be offered only within studies, as an addition to standard therapy: hyperthermia is not a proven standard, and a benefit has not been established. HIFU, which destroys a prostate tumour with heat and pressure, is a separate focal method – also not a standard.
For the patient: hyperthermia makes sense only for a specific diagnosis and within a plan with radiotherapy or chemotherapy, assessed by the tumour board and radiation oncologist. If a clinic cannot name such an indication and plan, or offers heat instead of standard treatment, ask questions.
Whole-body hyperthermia and private offers: what to watch out for
Whole-body or «fever» hyperthermia as a stand-alone course lacks convincing evidence: Germany’s Cancer Information Service rates whole-body hyperthermia as unproven and induced fever as too dangerous. Modulated electro-hyperthermia, sold as «oncothermia», lacks proof too: a systematic review found no evidence that it prolongs life or improves its quality. Such courses may come with infusions and supplements or replace chemotherapy – the most dangerous case: the tumour can grow while time for proven treatment is lost. For supportive methods, see integrative oncology.
Before agreeing, ask what diagnosis and standard treatment the heat is for, how tumour temperature is measured, and what a session and the course cost. Sound use has three marks: a proven indication or a clinical trial, combination with radiotherapy or chemotherapy, and temperature control. Side effects of local and regional hyperthermia usually stay in the heated area: redness, swelling, pain or discomfort, less often burns or blisters. Metal implants or a pacemaker in the heating zone may rule out certain devices – the doctor checks this.
Frequently asked questions
Can hyperthermia cure cancer without chemotherapy or radiotherapy?
No, hyperthermia is not considered a cancer treatment on its own. It is meant to strengthen radiotherapy or chemotherapy, and the trials that showed a benefit compared standard treatment with and without heat. If heat is offered instead of standard treatment, discuss it with an oncologist before paying.
What is oncothermia, and does it work?
Oncothermia is a form of electro-hyperthermia: tissue is heated with radio waves through electrodes on the body. A systematic review found no evidence that electro-hyperthermia prolongs life or improves its quality; benefit was shown only for «standard» hyperthermia with tumour temperature measured during treatment. Such methods are offered mainly by alternative and complementary medicine providers.
Is hyperthermia available everywhere in Germany?
No, hyperthermia is not widely available; the German sarcoma guideline mentions this explicitly. So the first question is whether hyperthermia is indicated for your diagnosis together with radiotherapy or chemotherapy; only then is a hospital chosen where both treatments can follow one schedule.
How AlenMed organises hyperthermia as part of cancer treatment
First the diagnosis and main plan, then the question of heat. AlenMed sends reports, histology and imaging to a partner clinic’s tumour board and asks whether hyperthermia with radiotherapy or chemotherapy is indicated for this diagnosis, and where it is available.
Sessions follow the radiotherapy or chemotherapy schedule, so the stay covers the whole course, and the clinic’s cost estimate (Kostenvoranschlag) includes both treatments. The amount depends on the type of hyperthermia, the number of sessions in the treatment plan, inpatient or outpatient care and accommodation; only the estimate gives a figure (see radiotherapy cost). Dendritic cell therapy, which families also ask about, is a separate method. AlenMed arranges interpreters and the visa invitation; its office is in Munich, partner clinics are across Germany.
This material is for information only and is not an offer. Whether hyperthermia is appropriate is decided by a doctor after an in-person examination.
News on this topic
Charité treats first beta-thalassemia patient with CRISPR
At Berlin Charité, a 19-year-old beta-thalassemia patient became the first in Germany to receive the newly approved CRISPR gene therapy Exagamglogene Autotemcel.
Real-World Breast Cancer Study Confirms High Five-Year Survival Rates in Germany
A landmark study of over 43,000 German patients reveals a five-year invasive disease-free survival rate of 82.9 percent in early hormone receptor-positive breast cancer.
FDA Approves Jülich Diagnostic Radiotracer FET for Brain Tumor Imaging
The FDA approves the diagnostic radiotracer FET (Pixclara®) for evaluating brain gliomas, highlighting decades of neuro-oncology research at Forschungszentrum Jülich.
